BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deville C, Garrouste C, Coppo P, Evrard B, Lautrette A, Heng AE. Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome: A case report and literature review. Medicine (Baltimore) 2016;95:e5007. [PMID: 27684863 DOI: 10.1097/MD.0000000000005007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 García-martín E, Manrique-rodríguez S, Martínez Fernández-llamazares C, Goicoechea-diezhondino M, Álvarez-blanco O, García-morín M, Sanjurjo-sáez M. Variability in management and outcomes of therapy with eculizumab in atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2019;7:525-33. [DOI: 10.1080/21678707.2019.1703108] [Reference Citation Analysis]
2 Patterson JM, Bolster L, Larratt L. Case Series of 3 Patients Diagnosed With Atypical Hemolytic Uremic Syndrome Successfully Treated With Steroids, Plasmapheresis, and Rituximab. Can J Kidney Health Dis 2018;5:2054358117747262. [PMID: 29308213 DOI: 10.1177/2054358117747262] [Reference Citation Analysis]
3 Philipponnet C, Desenclos J, Brailova M, Aniort J, Kemeny JL, Deville C, Fremeaux-Bacchi V, Souweine B, Heng AE. Cobalamin c deficiency associated with antifactor h antibody-associated hemolytic uremic syndrome in a young adult. BMC Nephrol 2020;21:96. [PMID: 32164588 DOI: 10.1186/s12882-020-01748-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]